Partnership with Swinburne & Cooper Investors

Swinburne has signed a transformational $1 million agreement with Hearts and Minds Investments Ltd and Cooper Investors supporting vital mental health medical research.

Partnership with Swinburne & Cooper Investors

September 23, 2021
Swinburne has signed a transformational $1 million agreement with Hearts and Minds Investments Ltd and Cooper Investors supporting vital mental health medical research.
Read Transcript

Swinburne’s Centre for Human Psychopharmacology has received a further $1 million in philanthropic funding for their research, which will use the latest neuroimaging technology.

In summary:

  • Swinburne has received a transformational commitment of $1 million from Hearts and Minds Investments Ltd to support key mental health medical research
  • Funding will support programs to boost emotional intelligence (EI) in lower socioeconomic status primary and secondary schools, and explore the connection between the gut microbiome and cognitive decline
  • Researchers from Swinburne’s Centre for Human Psychopharmacology will blend fundamental research with the latest technologies to deliver key advances for mental health

 

Swinburne has signed a new agreement with Hearts and Minds Investments Ltd and Cooper Investors that will see a further $1 million invested into medical research by 2023. This takes the total investment from Hearts and Minds Investments Ltd to $1.7 million.

The gift will support research by Swinburne’s Centre for Human Psychopharmacology into improving emotional intelligence (EI) in schools, as well as the link between gut microbiome and healthy cognitive ageing.

 

Delivering lasting impact

Swinburne’s Centre for Human Psychopharmacology brings together institutions from around the globe and uses the latest technologies and research methodologies to develop new medicine and drive a new generation of medical research in Australia.

The research will apply scientific rigour and the latest technology to research biological determinants of cognitive health across one's lifespan. It will also include trials with Swinburne’s bespoke neuroimaging capability and interactive online research programs for participants.  The research supports Swinburne’s vision of bringing people and technology together to build a better world.

Swinburne’s Vice-Chancellor and President, Professor Pascale Quester, says the benefits of the research, made possible by support from Hearts and Minds and Cooper Investors, will be felt for generations to come.

‘Swinburne is proud to be partnering with Cooper Investors and Hearts and Minds. This investment will support early career researchers and enable them to make real advances in key areas of health and medical research,’ Professor Quester says.

‘Blending human insight and endeavour with technology, this research will help understand how the health of our microbiome affects cognitive decline as we age, and we can explore how to drive school retention and performance through increased emotional intelligence.  It is vital research like this that is helping us achieve our vision of bringing humans and technology together to build a better world.’

 

Investing in our future

Since 2019, the philanthropic partnership between Swinburne and Hearts and Minds has contributed to the overall improvement of mental health, intuition and wellbeing of Australians.

CEO of Hearts and Minds Investments Ltd and Swinburne alum, Paul Rayson, says the organisation has a passion for growing sustainable, progressive partnerships, like the one with Swinburne.

‘Investing in research is investing in our future – a long-term investment into making the world a better place,’ Rayson says.

‘There are many quality of life issues that can be enhanced by a better understanding of human cognition, mood and behaviour. We see the world-class research conducted at Swinburne as having the potential to make a positive impact and lead to improved treatments and management of cognitive health,’ he says.

‘When it comes to medical research, everyone is hoping to get that breakthrough, which can be rare, but when you do get it – it has a huge benefit.’

Cooper Investors, that nominated Swinburne as a beneficiary for Hearts and Minds funds, said: ‘Philanthropy or the act of contribution is a core value at Cooper Investors.’

‘We recognise mental health as the health challenge of a generation and believe that, wherever possible, we should look to support institutions like Swinburne to conduct vital translational research in this area. We want to use our philanthropy program to support world-class research and programs to better the mental health of communities across the country.’

 

 

Swinburne’s Centre for Human Psychopharmacology has received a further $1 million in philanthropic funding for their research, which will use the latest neuroimaging technology.

In summary:

  • Swinburne has received a transformational commitment of $1 million from Hearts and Minds Investments Ltd to support key mental health medical research
  • Funding will support programs to boost emotional intelligence (EI) in lower socioeconomic status primary and secondary schools, and explore the connection between the gut microbiome and cognitive decline
  • Researchers from Swinburne’s Centre for Human Psychopharmacology will blend fundamental research with the latest technologies to deliver key advances for mental health

 

Swinburne has signed a new agreement with Hearts and Minds Investments Ltd and Cooper Investors that will see a further $1 million invested into medical research by 2023. This takes the total investment from Hearts and Minds Investments Ltd to $1.7 million.

The gift will support research by Swinburne’s Centre for Human Psychopharmacology into improving emotional intelligence (EI) in schools, as well as the link between gut microbiome and healthy cognitive ageing.

 

Delivering lasting impact

Swinburne’s Centre for Human Psychopharmacology brings together institutions from around the globe and uses the latest technologies and research methodologies to develop new medicine and drive a new generation of medical research in Australia.

The research will apply scientific rigour and the latest technology to research biological determinants of cognitive health across one's lifespan. It will also include trials with Swinburne’s bespoke neuroimaging capability and interactive online research programs for participants.  The research supports Swinburne’s vision of bringing people and technology together to build a better world.

Swinburne’s Vice-Chancellor and President, Professor Pascale Quester, says the benefits of the research, made possible by support from Hearts and Minds and Cooper Investors, will be felt for generations to come.

‘Swinburne is proud to be partnering with Cooper Investors and Hearts and Minds. This investment will support early career researchers and enable them to make real advances in key areas of health and medical research,’ Professor Quester says.

‘Blending human insight and endeavour with technology, this research will help understand how the health of our microbiome affects cognitive decline as we age, and we can explore how to drive school retention and performance through increased emotional intelligence.  It is vital research like this that is helping us achieve our vision of bringing humans and technology together to build a better world.’

 

Investing in our future

Since 2019, the philanthropic partnership between Swinburne and Hearts and Minds has contributed to the overall improvement of mental health, intuition and wellbeing of Australians.

CEO of Hearts and Minds Investments Ltd and Swinburne alum, Paul Rayson, says the organisation has a passion for growing sustainable, progressive partnerships, like the one with Swinburne.

‘Investing in research is investing in our future – a long-term investment into making the world a better place,’ Rayson says.

‘There are many quality of life issues that can be enhanced by a better understanding of human cognition, mood and behaviour. We see the world-class research conducted at Swinburne as having the potential to make a positive impact and lead to improved treatments and management of cognitive health,’ he says.

‘When it comes to medical research, everyone is hoping to get that breakthrough, which can be rare, but when you do get it – it has a huge benefit.’

Cooper Investors, that nominated Swinburne as a beneficiary for Hearts and Minds funds, said: ‘Philanthropy or the act of contribution is a core value at Cooper Investors.’

‘We recognise mental health as the health challenge of a generation and believe that, wherever possible, we should look to support institutions like Swinburne to conduct vital translational research in this area. We want to use our philanthropy program to support world-class research and programs to better the mental health of communities across the country.’

 

 

Disclaimer: This material has been prepared by Swinburne's Centre For Human Psychopharmacology, published on Sep 23, 2021. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
August 19, 2021

The Florey: Innovative new approach for Parkinson’s disease

Florey researchers have partnered with engineers from ANU to develop and study a new type of hydrogel that could radically transform a novel stem cell treatment for Parkinson’s disease.

Read More
August 10, 2021

Podcast: Minding Your Mind

Prof Ian Hickie, of the Brain and Mind Centre has launched a podcast, Minding Your Mind, to explore all aspects of mental health; the different types of mental health issues we can experience, their causes, how they affect us, and what we can do to get help and find solutions.

Read More
August 3, 2021

Australian breakthrough to stop heart arteries from clogging

Victor Chang scientist has led landmark research that has the potential to stop arteries of the heart from becoming clogged by targeting a particular gene.

Read More
July 16, 2021

Victor Chang: Discovery of live-saving heart attack treatment

New research out of Victor Chang brings treatment for Australia’s biggest killer a step closer, this exciting discovery could lead to new preventative treatments for atherosclerosis and coronary artery disease.

Read More
February 23, 2021

Podcast: Paul Rayson, Mental Wellth

This episode of Mental Wellth looks at how mental health is funded and Paul Rayson discusses how vehicles like Hearts and Minds are an emerging funding solution.

Read More
December 9, 2020

Beneficiary Profile: MS Research Australia

MS Research Australia is the largest non-government funder of research into multiple sclerosis (MS). They have invested over $44.3m into MS research via major collaborative research platforms and investigator-led projects.

Read More
November 23, 2020

Thank you from MS Research Australia

MS Research Australia has a message of thanks to the Hearts and Minds Community for the support we provide them and their research to Stop and Reverse MS within the next 10 years.

Read More
October 12, 2020

Beneficiary Profile: Victor Chang

Cardiovascular disease is the number one cause of death globally and costs the Australian economy $12 billion each year. Every 12 minutes, one Australian dies from the disease. This is why the Victor Chang Cardiac Research Institute is dedicated to finding cures through their world class research.

Read More
September 27, 2020

Thank you from Prof Pat McGorry, Orygen

Professor Pat McGorry, Executive Director of Orygen has a message of thanks to Cooper Investors and HM1 shareholders for the support we provide them and their research into the mental health of young people.

Read More
September 25, 2020

The ASX company championing hearts and minds

Swinburne’s Centre for Human Psychopharmacology is honoured to have been selected by one of Hearts and Minds’ fund managers, Cooper Investors, as a recipient of funding.

Read More
September 23, 2020

Silent wave' of brain damage could follow pandemic

Australia urgently needs to prepare for a "silent wave" of COVID-19, which appears to be taking the form of long-term neurological side effects following infection with the virus.

Read More
September 8, 2020

Beneficiary Profile: Black Dog Institute

1 in 5 of us will experience symptoms of mental illness in any given year. In Australia that’s around 5 million people. And roughly 60% of these people won’t seek help. Learn what Black Dog is doing to create a mentally healthier world for everyone.

Read More
September 1, 2020

ABC: Cash for Causes

An increasing number of LICs are being created to spit out cash for causes. HM1 is such a LIC that top fund managers donate their time too. This year it paid out $9.3m to medical research. HM1's Chairman Chris Cuffe, speaks to Elysse Morgan on ABC's The Business.

Read More
September 1, 2020

Hearts and Minds donates almost $10m to charity

Listed investment company Hearts and Minds Investments (ASX: HM1) will donate $5.1 million to 10 medical research this week, in addition to the $4.1 million it already donated in March. [Financial Standard]

Read More
September 1, 2020

Hearts and Minds keep shining the light on medical research

CEO Paul Rayson says HM1's results are outstanding given the bumpy period. COVID-19 has shone a light on medical research and he's proud to contribute to the field and help support people during these tough times.

Read More